CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
6.87
-0.44 (-6.05%)
At close: Jun 16, 2025, 4:00 PM
11.96
+5.09 (74.14%)
Pre-market: Jun 17, 2025, 7:18 AM EDT
Company Description
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors.
The company was incorporated in 2021 and is based in South San Francisco, California.
CERo Therapeutics Holdings, Inc.
Country | United States |
Founded | 2017 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 8 |
CEO | Christopher Ehrlich |
Contact Details
Address: 201 Haskins Way, Suite 230 South San Francisco, California 94080 United States | |
Phone | (650) 407-2376 |
Website | cero.bio |
Stock Details
Ticker Symbol | CERO |
Exchange | NASDAQ |
Stock Type | Common Stock |
Share Class | Class A Shares |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001870404 |
ISIN Number | US71902K3032 |
Employer ID | 87-1088814 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Christopher B. Ehrlich M.B.A. | Chief Executive Officer and Chair |
Andrew Albert Kucharchuk M.B.A. | Chief Financial Officer |
Dr. Kristen Pierce Ph.D. | Chief Development Officer |
Dr. Lawrence Corey M.D. | Co-founder and Head of Scientific Advisory Board |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 16, 2025 | 424B3 | Prospectus |
Jun 13, 2025 | 8-K | Current Report |
Jun 11, 2025 | 8-K | Current Report |
Jun 6, 2025 | 424B3 | Prospectus |
Jun 6, 2025 | 8-K | Current Report |
Jun 2, 2025 | 8-K | Current Report |
May 29, 2025 | EFFECT | Notice of Effectiveness |
May 29, 2025 | 8-K | Current Report |
May 27, 2025 | POS AM | Post-Effective amendments for registration statement |
May 15, 2025 | 10-Q | Quarterly Report |